Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- Data From Enzo Therapeutics' Phase II Study Of Crohn's Disease Presented At Prestigious Gastroenterology Conference
- New Report Finds Obesity Epidemic Increases, Mississippi Weighs In As Heaviest State
- Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer
- First Choice Of Renal Function Tests In Hepatectomy Patients
- Cutting Breast Cancer Risk And Treating Symptoms Of Menopause With Hormone Mix
- Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial
- Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial
- Amarillo Biosciences And CytoPharm Announce Start Of Enrollment For Hepatitis C Study In Taiwan
- ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic Leukaemia
- National Community Pharmacists Association Statement About House Democrats' Bill On Health Care Reform
Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
For men younger than 50 with prostate cancer, undergoing a radical prostatectomy can greatly increase their chances for long-term survival, according to a new study from Henry Ford Hospital.
Results from the study done on the National SEER database show that the surgical procedure improves the 5-, 10-, 15- and 20-year survival for younger patients, when compared with other standard treatments such as radiotherapy or watchful waiting.
“When given the choice between surgery, watchful waiting or external beam radiotherapy, patients younger than 50 with moderately and poorly differentiated prostate cancers have better long-term overall and cancer-specific survival when they opt for surgery,” says study author Naveen Pokala, M.D., an urologist with Henry Ford Hospital.
Based on findings from the study, Dr. Pokala and co-author Mani Menon, M.D., director of Henry Ford’s Vattikuti Urology Institute, strongly recommend retropubic radical prostatectomy - a surgical procedure that removes the entire prostate gland plus some of the tissue around it - as the treatment of choice for prostate cancer patients under the age of 50.
Prostate cancer affects one in six men in the United States during his lifetime, but according to the American Cancer Society only one in 35 will die of it.
Although the majority of all prostate cancer are diagnosed in men older than 65, its prevalence is growing among men younger than 50. In fact, about one in 10,000 men under the age of 40 will be diagnosed this year with prostate cancer.
To determine which treatment option offers the best chance for long-term survival for younger prostate cancer patients, Pokala and Menon studied more than 8,200 men under age 50 with prostate cancer.
Among the study group, 73 percent were white and about 22 percent were black. The mean age was 46, and over 70 percent had moderately and 22 percent had poorly differentiated cancers. Of the patients, 1,065 were managed with no definitive treatment (watchful waiting); 6,614 (79.9 percent) with radical retropubic prostatectomy; and 600 with external beam radiotherapy.
The cancer-specific survival in the NDT group was 78 percent at 16 years, in the radiation group was 63 percent at 17 years; and 94 percent in the radical prostatectomy at 21 years. On a subset analysis the outcome was significantly better after radical prostatectomy in patients with moderately and poorly differentiated prostate cancer.
Overall, the study shows the 5-year, 10-year, 15-year and 20-year overall survival and cancer specific survival is significantly increased in patients who were less than 50 years of age with moderately and poorly differentiated cancers in the surgery group.
The results were presented in Chicago at the recent American Urological Association’s annual meeting.
Source:
Dwight Angell
Henry Ford Health System
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.